Skip to main content
NIH funding notice RFA-AG-17-059

Multimorbidity in Alzheimers Disease Impacts Choice of Ancillary Treatments (R21/R33)

Closed on January 12, 2017.

Posted
October 27, 2016
Close date
January 12, 2017
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $641,129 in first-year total cost, median $320,565.

Most frequent study sections

  1. Special Emphasis Panel[ZAG1 ZIJ-3 (A1)]2

Most frequent institutions

  1. KAISER FOUNDATION RESEARCH INSTITUTE1
  2. NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
Competing awards under RFA-AG-17-059 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2017Enhanced Quality in Primary Care for Elders with Diabetes and Dementia (EQUIPED-ADRD)1R21AG057291-01BLAUM, CAROLINE SCHODOSH, JOSHUANEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY$337,475ZAG1
2017Optimal Medication Management in Alzheimer's Disease and Dementia1R21AG057289-01BAYLISS, ELIZABETH ABOYD, CYNTHIA MELINDAKAISER FOUNDATION RESEARCH INSTITUTE, CA$303,654ZAG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.